

Creative Biolabs' Afuco™ platform – the key to your ADCC+ success

Our Afuco™ technology platform incorporates cuttingedge glycoengineering technology and expertise to enable us to optimize the ADCC activity of therapeutic antibodies. Powered by Afuco ™ technology, we provide our clients a comprehensive antibody modification protocol that allows oligosaccharides in the Fc region to be free of any fucose units. Fucosyltransferase engineered stable cell lines are available for subsequent ADCC antibody preparation.

ADCC Enhancement Technology 7